Allakos — Company Overview, News & Financial Data
Allakos develops monoclonal antibody therapies for immunologic and inflammatory diseases to improve patient lives.
Allakos
About
Allakos (NASDAQ:ALLK) is a biopharmaceutical company focused on developing innovative therapies that target immunologic and inflammatory diseases. With a commitment to advancing the science of monoclonal antibodies, Allakos is diligently working on a portfolio of treatments aimed at significantly improving the lives of patients suffering from a variety of disorders. The company's lead projects are designed to address unmet medical needs in diseases characterized by excessive activation of certain immune cells, offering potential new pathways to treatment. Allakos is dedicated to pushing the boundaries of medicine to provide novel solutions for patients across the globe, with the objective of not only managing but potentially overcoming challenging immune and inflammatory conditions.
Snapshot
Operations
Products and/or services of Allakos
- Development of antolimab (AK002), targeting eosinophilic and mast cell-related diseases.
- Research into therapies for eosinophilic gastritis and gastroenteritis focused on reducing inflammatory cell infiltration.
- Investigations into treatments for urticaria and severe allergic reactions, aiming to control symptoms.
- Preclinical work on novel monoclonal antibodies targeting immune system dysregulation.
- Expansion of therapeutic pipeline into dermatological conditions with emphasis on chronic urticaria.
- Exploration of potential treatments for eosinophilic esophagitis, seeking to alleviate swallowing difficulties.
Allakos executive team
- Dr. Robert Alexander Ph.D.Chair of the Board, CEO & Director
- Dr. Adam L. Tomasi Ph.D.President
- Mr. H. Baird Radford IIIChief Financial Officer
- Mr. Alan ChangDirector of Medical Affairs & Data Analytics
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift